Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 33c, Beats on Revenue; Offers FY24 Revenue Guidance

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.56, $0.33 better than the analyst estimate of $0.23. Revenue for the quarter came in at $122.7 million versus the consensus estimate of $111.77 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2024 revenue of $455-475 million, versus the consensus of $462.4 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.

You May Also Be Interested In

• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
• 19 Millions Barrels of Oil flowed out of the Hormuz Strait yesterday - Trump